Online citations, reference lists, and bibliographies.
← Back to Search

Pemetrexed Plus Carboplatin In Elderly Patients With Malignant Pleural Mesothelioma: Combined Analysis Of Two Phase II Trials

G. Ceresoli, B. Castagneto, P. Zucali, A. Favaretto, M. Mencoboni, F. Grossi, D. Cortinovis, G. Conte, A. Ceribelli, A. Bearz, S. Salamina, F. De Vincenzo, F. Cappuzzo, M. Marangolo, V. Torri, A. Santoro
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m−2 and carboplatin AUC 5 mg ml−1 min−1 intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those ⩾70 years old. A total of 178 patients with an ECOG performance status of ⩽2 were included. Median age was 65 years (range 38–79), with 48 patients ⩾70 years (27%). Grade 3–4 haematological toxicity was slightly worse in ⩾70 vs <70-year-old patients, with neutropenia observed in 25.0 vs 13.8% (P=0.11), anaemia in 20.8 vs 6.9% (P=0.01) and thrombocytopenia in 14.6 vs 8.5% (P=0.26). Non-haematological toxicity was mild and similar in the two groups. No significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P=0.47), time to progression (7.2 vs 7.5 months, P=0.42) and survival (10.7 vs 13.9 months, P=0.12). Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
This paper references
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1016/S0889-8588(05)70275-6
Aging and cancer in America. Demographic and epidemiologic perspectives.
R. Yancik (2000)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1200/JCO.2007.10.6583
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.
S. Lichtman (2007)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1200/JCO.2007.10.6559
Comprehensive geriatric assessment for older patients with cancer.
M. Extermann (2007)
10.1016/S1470-2045(06)70662-3
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.
A. Ceribelli (2006)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1002/ijc.20820
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1093/AJE/KWH025
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
10.1200/JCO.2006.06.7835
Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
G. Weiss (2006)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.1016/J.EJCA.2006.07.011
Biology and management of malignant pleural mesothelioma.
P. Zucali (2006)
SEER) Program (2007) SEER*Stat Database: Incidence -SEER 9 Regs Limited-Use
Epidemiology Surveillance (1973)
Pemetrexed in malignant pleural mesothelioma.
M. Hazarika (2005)
10.1214/SS/1177011454
A Survey of Exact Inference for Contingency Tables
A. Agresti (1992)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1200/JCO.2006.09.2759
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups.
A. Kumar (2007)
A (2007a) Assessment of tumor response in malignant pleural mesothelioma
GL Ceresoli (2007)
International Society of Geriatric Oncology Chemotherapy Taskforce (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients
SM Lichtman (2007)
Regression Models and Life-Tables
D.
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1200/JCO.2004.02.175
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
L. Talarico (2004)
10.1056/NEJM199912303412706
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
L. Hutchins (1999)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.2003.08.010
Participation of patients 65 years of age or older in cancer clinical trials.
J. Lewis (2003)
Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration
L Talarico (2004)
The International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma
VW Rusch (1995)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Pemetrexed plus carboplatin in elderly patients with MPM GL Ceresoli et al
for the Gruppo di Studio Tumori Polmonari Veneto (GSTPV) (2003) Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma. A multicentric phase II study
A G Favaretto
10.1200/JCO.2005.05.1359
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
J. Francart (2006)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
A (2007b) Multidisciplinary treatment of malignant pleural mesothelioma
GL Ceresoli (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1080/00031305.1996.10473544
A COMPARISON OF APPROXIMATE INTERVAL ESTIMATORS FOR THE BERNOULLI PARAMETER
Lawrence M Leemis (1993)



This paper is referenced by
10.1016/j.pneumo.2012.12.003
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†
Paul Baas (2015)
10.1002/9781119952930.CH49
Interstitial Lung Disease and Lung Cancer
Christopher Dyer (2012)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.18773/AUSTPRESCR.2011.076
Medical management of mesothelioma
Rayleen V. Bowman (2011)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Giovanni Luca Ceresoli (2019)
10.4137/CMRO.S1583
Platinum and Pemetrexed Combination in Advanced Solid Tumors
Giovanna Finocchiaro (2010)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1158/1078-0432.CCR-10-2873
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
P. A. Zucali (2011)
10.1097/COC.0b013e3181d31f02
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
C. Pinto (2011)
10.4155/CLI.11.72
Treatment of malignant pleural mesothelioma: current status and future directions
Paolo Andrea Zucali (2011)
10.1007/S12094-009-0308-Z
Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine
J. G. Blesa (2009)
10.5301/tj.5000436
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
10.4137/CMT.S1166
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma
Paolo Andrea Zucali (2010)
10.1097/CCO.0b013e328324bc30
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
R. Stahel (2009)
10.1016/S0761-8425(07)78149-4
Prise en charge dignostique et thrapeutique du msothliome pleural malin en 2007
E. Porret (2007)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
10.1055/s-0031-1272874
Update on malignant pleural mesothelioma.
N. Campbell (2011)
10.1684/BDC.2013.1857
Mésothéliomes malins pleuraux : le point en 2013
Kevin Campbell (2013)
10.2217/LMT.15.16
Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?
Andrea S. Wolf (2015)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
10.1016/S1877-1203(13)70439-7
Prise en charge du mésothéliome pleural malin en 2013
J. Margery (2013)
10.2147/OTT.S115631
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma
Manal El-Hamamsy (2016)
10.1016/j.bcp.2016.07.012
New therapeutic strategies for malignant pleural mesothelioma
M. Bonelli (2017)
10.1007/978-3-030-33832-9_20
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies
Lory Santarelli (2020)
10.1007/s11912-011-0172-1
Medical Treatment of Mesothelioma: Anything New?
N. Takigawa (2011)
10.1016/S1877-1203(14)70610-X
Mésothéliome pleural malin : la chimiothérapie est-elle la seule option thérapeutique ?
Arnaud Scherpereel (2014)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1097/CCO.0b013e3283297a50
Current World Literature
(2009)
10.1007/978-3-662-48727-3_39
Pleuramesotheliom beim alten und geriatrischen Patienten
Martin Steins (2018)
10.18632/oncotarget.16398
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
F. Mairinger (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar